On June 30, 2021 BeiGene reported that it been approved to stage a $3 billion IPO on the Shanghai Star Stock Exchange (Press release, BeiGene, JUN 30, 2021, View Source [SID1234584527]). It will be the first Chinese biopharma to be listed in Shanghai, Hong Kong and the US. According to a Caixin report, BeiGene’s propectus meets the listing conditions and information disclosure requirements of the STAR Market, but regulators asked BeiGene to explain how it will protect the interests of domestic shareholders. Founded in 2010, BeiGene develops molecularly targeted and immuno-oncology drug candidates to treat cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!